靶向超声造影剂BR55的研究进展  

Research Progress of Targeted Ultrasound Contrast Agent BR55

作　　者：张馨悦 吕珂[1] 李建初[1] 姜玉新[1] 孝梦甦[1] ZHANG Xinyue;LÜ Ke;LI Jianchu;JIANG Yuxin;XIAO Mengsu(Department of Ultrasound,PUMC Hospital,CAMS and PUMC,Beijing 100730,China;Department of Ultrasound,Fangshan Hospital of Beijing University of Chinese Medicine,Beijing 102488,China)

机构地区：[1]中国医学科学院,北京协和医学院,北京协和医院超声科,北京100730 [2]北京中医药大学房山医院超声科,北京102488

出　　处：《中国医学科学院学报》2022年第1期118-122,共5页Acta Academiae Medicinae Sinicae

基　　金：国家自然科学基金(81873902);中国医学科学院医学与健康科技创新工程(2016-I2M-3-005)。

摘　　要：BR55是以血管内皮生长因子受体2为靶点的靶向超声造影剂,可用于检测肿瘤新生血管形成提高诊断准确率。国外已有学者应用BR55进行人体超声分子成像,并显示出良好的安全性和耐受性。本文从BR55组成及特性、动物实验及临床应用等方面对BR55在评估肿瘤新生血管的研究进展进行综述。BR55 is an ultrasound contrast agent targeting vascular endothelial growth factor receptor 2,which can be used to detect tumor neovascularization and improve the diagnostic accuracy.Overseas researchers have used BR55 for human ultrasound molecular imaging,which showed good safety and tolerance.We reviewed the research progress on BR55 applied in the evaluation of tumor neovascularization from the composition,characteristics,animal experiments,and clinical studies of BR55.

关 键 词：靶向超声造影剂 超声分子成像 血管内皮生长因子受体 

分 类 号：R445.1[医药卫生—影像医学与核医学]